Rabail Soomro, MD
NPI 1124515465 · Endocrinology, Diabetes & Metabolism Physician · Melbourne, FL
Enrolled with Medicare as Practitioner - Endocrinology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1124515465
- Entity type
- Individual
- Primary specialty
- Endocrinology, Diabetes & Metabolism PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Female
- Sole proprietor
- No
- License
- ME161023 (FL)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
8 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,355 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Visit Complexity Inherent to Evaluation and Management Associated With Medical Care Services That Serve As the Continuing Focal Point for All Needed Health Care Services And/Or With Medical Care Services That Are Part of Ongoing Care Related to a Patient'SG2211 | 546 | $16 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 419 | $124 |
| Continuous Monitoring of Blood Sugar Level in Tissue Fluid Using Sensor Under Skin With Interpretation and Report95251 | 138 | $33 |
| New Patient Office Or Other Outpatient Visit With Moderate Level of Medical Decision Making, If Using Time, 45 Minutes Or More99204 | 88 | $164 |
| Established Patient Office Or Other Outpatient Visit With High Level of Medical Decision Making, If Using Time, 40 Minutes Or More99215 | 60 | $171 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 49 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Levothyroxine Sodium | 294 | 102 |
| Semaglutidebrand: Ozempic | 270 | 85 |
| Metformin Hcl | 175 | 70 |
| Empagliflozinbrand: Jardiance | 162 | 52 |
| Insulin Aspartbrand: Novolog Flexpen | 117 | 43 |
| Insulin Glargine,hum.rec.anlogbrand: Lantus Solostar | 104 | 39 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$254 across 3 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2018-04-20
- Last updated
- 2023-09-22
- Certified
- 2023-09-22
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.